54However, it must be noted that, in the present case, the Commission has not departed from the CHMP opinion, since the content of that opinion, as well as that of the assessment report on which it is based, is an integral part of the reasoning behind that decision, in particular as regards the scientific evaluation of the medicinal product at issue (see paragraphs 16 and 35 above). The Commission has therefore endorsed the findings in that opinion. Consequently, it must be held that the judicial review to be undertaken by the Court, in particular its review of whether there has been a manifest error of assessment, must be carried out on the basis of all the considerations set out in that opinion and the assessment report mentioned above (see, to that effect, judgment of 5 December 2018, Bristol-Myers Squibb Pharma v Commission and EMA, T‑329/16, not published, EU:T:2018:878, paragraph 98).